Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 59.51M | 66.09M | 67.67M | 57.53M | 52.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.51M | 66.09M | 67.67M | 57.53M | 52.86M |
| Cost of Revenue | 315.91M | 330.35M | 358.04M | 384.07M | 414.29M |
| Gross Profit | -256.40M | -264.26M | -290.37M | -326.54M | -361.43M |
| SG&A Expenses | 167.08M | 156.46M | 150.62M | 152.19M | 150.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 482.99M | 486.81M | 508.66M | 536.26M | 564.88M |
| Operating Income | -423.48M | -420.72M | -440.99M | -478.73M | -512.02M |
| Income Before Tax | -399.98M | -394.60M | -412.69M | -445.81M | -480.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -399.98 | -394.60 | -412.69 | -445.81 | -480.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -399.98M | -394.60M | -412.69M | -445.81M | -480.19M |
| EBIT | -423.48M | -420.72M | -440.99M | -478.73M | -512.02M |
| EBITDA | -414.40M | -411.24M | -431.22M | -468.77M | -501.87M |
| EPS Basic | -3.36 | -3.53 | -3.83 | -4.27 | -4.69 |
| Normalized Basic EPS | -2.10 | -2.21 | -2.39 | -2.66 | -2.89 |
| EPS Diluted | -3.36 | -3.53 | -3.83 | -4.27 | -4.69 |
| Normalized Diluted EPS | -2.10 | -2.21 | -2.39 | -2.66 | -2.89 |
| Average Basic Shares Outstanding | 478.08M | 448.33M | 433.34M | 419.28M | 410.09M |
| Average Diluted Shares Outstanding | 478.08M | 448.33M | 433.34M | 419.28M | 410.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |